American College of Rheumatology (ACR)

Global Survey Reveals that Few Children with Rheumatic Disease Report Contracting COVID-19, None Hospitalized

FOR IMMEDIATE RELEASE

 

Newswise — ATLANTA — Results from a large, international survey shows that only a small fraction of children with rheumatic diseases reported contracting COVID-19. Those who did become infected with COVID-19 all had benign outcomes and did not develop significant complications, despite the fact that most children were taking immunosuppressive medications. The research was presented at ACR Convergence, the American College of Rheumatology’s annual meeting (ABSTRACT #1685). 

The most common pediatric rheumatic disease is juvenile idiopathic arthritis (JIA), which is a group of chronic conditions that cause arthritis (joint swelling and inflammation) affecting children and teenagers. JIA may involve one or many joints, may also affect the eyes, and cause other symptoms, such as fevers or rash. 

As the COVID-19 pandemic surged worldwide in early 2020, the risk of COVID-19 and serious complications or death was unknown for children with rheumatic diseases. Many of these patients are treated with immunosuppressive medications that leave them more susceptible to infections.

“At the time, parents and physicians did not know whether to continue a child’s immunosuppressive medications to prevent COVID-19 and related complications,” says the study’s co-author, Jonathan S. Hausmann, MD, Instructor in Medicine at Harvard Medical School and a pediatric rheumatologist at Boston Children’s Hospital. 

To learn more about the impact of COVID-19 on children with rheumatic diseases, Dr. Hausmann and his fellow researchers analyzed data from the international COVID-19 Global Rheumatology Alliance Patient Experience Survey, a global patient registry. They sent surveys to parents of children with rheumatic diseases through patient support organizations and social media. Parents provided information on their child’s rheumatic disease diagnosis, medications, whether or not the child ever developed COVID-19 and any outcomes they experienced if they were infected.

The study collected data from April 3 to May 8, 2020 and includes 427 children under age 18. Most of the children in the study lived in the Americas, and were white, female and between 5 and 14 years old. Most had JIA, and they were taking either conventional synthetic or biologic disease-modifying antirheumatic drugs (DMARDs). Both classes of drugs suppress the immune system and help to control the arthritis, while also making children at increased risk of infection. The survey also included children with other pediatric rheumatic diseases such as lupus, dermatomyositis, and autoinflammatory diseases.

Among the 427 children in the study, only five, or 1.2%, were diagnosed with COVID-19, none of whom required hospitalization or had severe outcomes. Because the study is based on self-reported responses from parents who were engaged in social media or who were willing to fill out a survey, it may not fully represent all children with pediatric rheumatic diseases, and it may be more likely to include a healthier population, the researchers say. 

“These findings are important as policymakers and educators contemplate reopening schools with the pandemic still ongoing, and with parents and physicians struggling to make decisions of whether to send their children back to school,” says Dr. Hausmann. “Our study suggests that children with rheumatic disease should continue their immunosuppressive drugs during the pandemic, as it does not appear to place them at increased risk of COVID-19 related complications. Our findings support the recent ACR guidelines for managing immunosuppression during the pandemic.” 

Next, this research group plans to develop a prospective, international registry of people with rheumatic disease of all ages to assess long-term outcomes of the COVID-19 pandemic, explore the willingness to receive and assess the efficacy of a vaccine, assess the impact of the environment on COVID-19, and track the effects of the pandemic on the physical and mental health of participants over time, he adds.

 

 

###

 

About ACR Convergence

ACR Convergence, the ACR’s annual meeting, is where rheumatology meets to collaborate, celebrate, congregate, and learn. Join ACR for an all-encompassing experience designed for the entire rheumatology community. ACR Convergence is not just another meeting – it’s where inspiration and opportunity unite to create an unmatched educational experience. For more information about the meeting, visit https://www.rheumatology.org/Annual-Meeting, or join the conversation on Twitter by following the official hashtag (#ACR20).

 

About the American College of Rheumatology

The American College of Rheumatology (ACR) is an international medical society representing over 7,700 rheumatologists and rheumatology health professionals with a mission to empower rheumatology professionals to excel in their specialty. In doing so, the ACR offers education, research, advocacy and practice management support to help its members continue their innovative work and provide quality patient care. Rheumatologists are experts in the diagnosis, management and treatment of more than 100 different types of arthritis and rheumatic diseases.

 

ABSTRACT: Impact of the COVID-19 Pandemic Among Children with Rheumatic Diseases from Around the Globe 

Background/Purpose: 

Children with rheumatic diseases face unknown risks in the setting of the COVID-19 pandemic.  These children are often immunosuppressed due to their underlying disease or the medications used to treat them.  It is unknown whether children with rheumatic diseases are at increased risk of SARS CoV-2 infection or of developing serious disease complications should they become infected.  We report on the pediatric data from the COVID-19 Global Rheumatology Alliance (C19-GRA) Patient Experience Survey.

Methods:

The C19-GRA launched an international Patient Experience Survey for adults and parents of children with rheumatic disease, with or without COVID-19 infection. The survey was distributed online through patient support organizations and on social media. Parents completed the data on behalf of their children, including their child’s rheumatic disease diagnosis, medications, disease activity (as measured by a visual analog scale from 0-10, where 0=very good and 10=very poor), whether or not they developed COVID-19, and COVID-19 disease outcomes. Parents also completed the PROMIS Parent Proxy Scale v1.0 – Global Health 7. We report on data for children less than 18 years of age from April 3-May 8, 2020.

Results:

A total of 427 children are included in the analyses. Their demographics and clinical characteristics are shown in Table 1. Most respondents resided in the Americas (64.9%) and were white (73.3%), female (63.0%), and between the ages of 5-14 (64.9%). The majority of patients had juvenile idiopathic arthritis, and most were taking conventional synthetic DMARDs (csDMARDs) and/or biologic DMARDs (bDMARDs). The median disease activity score was 3 (IQR 1-6). The median T-score of the PROMIS Global Health measure was 43.9. Within this group, only 5 children (1.2%) were diagnosed with COVID-19, and none required hospitalization. Their COVID-19 disease experience is shown in Table 2. 

Conclusions:

In this international survey of children with rheumatic diseases, only a handful of children developed COVID-19, all of whom had benign outcomes.  Similar to otherwise healthy children, those with rheumatic disease do not seem to be at greater risk of developing COVID-19 or of COVID-19-related complications, even while taking immunosuppressive medications. Limitations of this study include a convenience sample of parents engaged in social media, which may not be representative of the pediatric rheumatology population. Data were self-reported and could not be verified. Future studies should assess the long-term effect of COVID-19 infection in patients with rheumatic disease, as well as assess the rates of complications such as Multisystem Inflammatory Syndrome in Children (MIS-C). Disclaimer:

The views expressed here are those of the authors and participating members of the COVID-19 Global Rheumatology Alliance and do not necessarily represent the views of the American College of Rheumatology, the European League Against Rheumatism (EULAR), or any other organization.

 



Filters close

Showing results

110 of 5809
Newswise: 267646_web.jpg
Released: 11-Jun-2021 2:10 PM EDT
Saliva can be more effective than nasopharyngeal swabs for COVID-19 testing
Elsevier

The collection of nasopharyngeal swab (NPS) samples for COVID-19 diagnostic testing poses challenges including exposure risk to healthcare workers and supply chain constraints.

Released: 11-Jun-2021 1:25 PM EDT
Physical Activity May Curb Health Care Worker Burnout
University of Georgia

More physical activity programming could mitigate the effects of stress and improve worker mental and emotional health.

Newswise: AI Predicts How Patients with Viral Infections, Including COVID-19, Will Fare
9-Jun-2021 6:05 PM EDT
AI Predicts How Patients with Viral Infections, Including COVID-19, Will Fare
University of California San Diego Health

UC San Diego School of Medicine researchers discovered gene expression patterns associated with pandemic viral infections, providing a map to help define patients’ immune responses, measure disease severity, predict outcomes and test therapies — for current and future pandemics.

Released: 10-Jun-2021 5:35 PM EDT
Senolíticos reducen síntomas de COVID-19 en estudios preclínicos
Mayo Clinic

Los investigadores de Mayo Clinic y sus colegas de la Universidad de Minnesota demostraron que la COVID-19 exacerba las consecuencias nocivas de las células senescentes en el cuerpo. En estudios preclínicos, los fármacos senolíticos descubiertos en Mayo redujeron considerablemente la inflamación, la enfermedad y la mortalidad debida a la infección por covid en ratones ancianos. Los resultados se publican en la revista Science.

Released: 10-Jun-2021 5:30 PM EDT
Senolíticos reduzem os sintomas de COVID-19 em estudos pré-clínicos
Mayo Clinic

Os pesquisadores da Mayo Clinic e colegas da Universidade de Minnesota mostraram que o COVID-19 intensifica o impacto prejudicial das células senescentes no corpo. Em estudos pré-clínicos, os medicamentos senolíticos descobertos na Mayo reduziram significativamente a inflamação, a gravidade da doença e a mortalidade da infecção por COVID em camundongos mais velhos. Essas conclusões foram publicadas na revista Science.

Newswise: FresnoSTateVaxImage2.jpg
Released: 10-Jun-2021 5:25 PM EDT
CSU Campuses Join COVID-19 College Vaccine Challenge
California State University (CSU) Chancellor's Office

The CSU pledges to be a Vaccine Champion University as part of new White House effort aimed at increasing vaccinations for younger Americans.

Released: 10-Jun-2021 5:05 PM EDT
الأدوية المحللة للشيخوخة تقلل من أعراض فيروس كورونا المستجد (كوفيد-19) في الدراسات ما قبل السريرية
Mayo Clinic

أظهر باحثو مايو كلينك وزملاؤهم في جامعة مينيسوتا أن فيروس كورونا المستجد (كوفيد-19) يفاقم التأثير الضار للخلايا الشائخة في الجسم. ففي الدراسات ما قبل السريرية، قللت الأدوية المحللة لالشيخوخة التي تم اكتشافها في مايو بشكل كبير من الالتهاب والمرض والوفيات الناجمة عن عَدوى فيروس كورونا المستجد في الفئران الأكبر سنًا. النتائج منشورة في مجلة ساينس.

7-Jun-2021 7:05 AM EDT
Study Examines the Effects of COVID-19 on Human Kidney Cells
American Society of Nephrology (ASN)

• The virus that causes COVID-19 can infect and replicate in human kidney cells, but this does not typically lead to cell death. • Kidney cells that already have features of injury may be more easily infected and develop additional injury.

Released: 10-Jun-2021 4:55 PM EDT
抗衰老药物在临床前研究中减少COVID-19症状。
Mayo Clinic

妙佑医疗国际(Mayo Clinic)的研究人员和明尼苏达大学的同事表明,COVID-19(2019冠状病毒病)加剧了体内衰老细胞的破坏性影响。在临床前研究中,妙佑医疗国际研发的抗衰老药物显著降低了老年实验鼠因COVID(冠状病毒病)感染引起的炎症、疾病和死亡率。该研究结果已发表在《科学》期刊中。

Newswise: blobid0_1623274320110.jpg
Released: 10-Jun-2021 4:45 PM EDT
How does COVID-19 affect patients with cancer? Largest U.S. study shares first results
University of Alabama at Birmingham

New findings include a significant increase in risk of death among patients who had recently had chemotherapy.


Showing results

110 of 5809

close
9.54166